-
05:38:20 PM

ALDX Stock News

03/16/23 7:00 AM
Nasdaq : ALDX
clinical trial
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑ 2191, an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration- approved treatment.
RHEA-AI
neutral
03/02/23 7:00 AM
Nasdaq : ALDX
FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics, Inc. today announced that the U.S. Food and Drug Administration accepted for Priority Review the New Drug Application for ADX-2191, an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma. The FDA assigned a Prescription Drug User Fee Act date of June 21, 2023. “The FDA’ s decision to grant Priority Review...
RHEA-AI
positive
03/01/23 7:00 AM
Nasdaq : ALDX
conferencesearnings
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
Aldeyra Therapeutics, Inc. will host a conference call at 8:00 a.m. ET Thursday, March 9, 2023 to report financial results for the year ended December 31, 2022 and discuss recent corporate highlights. The dial-in numbers are 470-1428 for domestic callers and 975-4839 for international callers. Aldeyra Therapeutics is a clinical-stage biotechnology...
RHEA-AI
neutral
02/28/23 7:00 AM
Nasdaq : ALDX
clinical trial
Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Aldeyra Therapeutics, Inc. today announced top-line results from a 12- month, vehicle-controlled, multicenter, parallel-group safety clinical trial of reproxalap, an investigational new drug, in dry eye disease patients. The primary endpoints of treatment-related serious adverse events in ocular safety were not observed in any patient.
RHEA-AI
neutral
02/23/23 7:00 AM
Nasdaq : ALDX
clinical trial
Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
Aldeyra Therapeutics, Inc. today announced the advancement of two investigational new drug candidates, ADX‑ 246 and ADX‑ 248, to clinical testing, pending completion of U.S. Food and Drug Administration Investigational New Drug requirements. “Highlighting Aldeyra’ s expansion to treatment of diseases that affect the retina and other areas of the body, ADX-246...
RHEA-AI
neutral
02/16/23 7:00 AM
Nasdaq : ALDX
clinical trial
Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Aldeyra Therapeutics, Inc. today announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑ 629, a novel, internally developed, investigational oral RASP modulator, for the treatment of minimal change disease and Sjögren-Larsson Syndrome. “Following the completion of successful proof-of-concept trials in psoriasis,...
RHEA-AI
neutral
02/09/23 7:00 AM
Nasdaq : ALDX
conferences
Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
Aldeyra Therapeutics, Inc., a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference. Brady’ s conversation with Marc...
RHEA-AI
neutral
02/07/23 7:00 AM
Nasdaq : ALDX
Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
Aldeyra Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has accepted the New Drug Application for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act date of November 23, 2023.
RHEA-AI
neutral
12/21/22 7:00 AM
Nasdaq : ALDX
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics, Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for ADX‑ 2191, an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA- approved therapy. The NDA submission is supported by a combination of published...
RHEA-AI
neutral